Mallory Pomales of Eagle Medical Services, LLC for their expertise and patience in assisting us with this undertaking. Robbin Weyant contributed significantly to the final editing and production efforts. Their significant contribution to this edition is sincerely appreciated. Baumann, Margy Lambert, Patricia Delarosa, and Theresa Lawrence, were instrumental in identifying authors, selecting additions to this edition, and reviewing submissions. McKinney, Casey Chosewood, and Deborah Wilson-without whom the BMBL would not be the respected resource it is today. Emmett Barkley, Jonathan Richmond, Robert W. It would have been impossible to publish this revision without recognizing the visionary leadership of the previous BMBL editors-Drs. We also recognize the hard work and contributions made by all who participated in preparation of the previous editions of BMBL we have built on their solid work and commitment Without them, the sixth edition of BMBL would not be possible. We wish to thank them all for their dedication and hard work. Over 200 of our scientific and professional colleagues contributed to the preparation of the sixth edition through participation in technical working groups and serving as reviewers, guest editors, and subject matter experts. In order to serve the needs of our community better, this edition includes new appendices on the following topics: inactivation and verification laboratory sustainability large-scale biosafety and clinical laboratory biosafety. Wherever possible, we clarified both the language and intent of the information provided. We harmonized the recommendations included in this edition with guidance issued and regulations promulgated by other organizations and federal agencies. This edition of BMBL includes revised sections, agent summary statements, and appendices. The BMBL should be used as a tool in the assessment and proposed mitigation steps in biomedical and clinical laboratories. The core principle of this document is protocol-driven risk assessment it is not possible for a single document to identify all of the possible combinations of risks and mitigations feasible in biomedical and clinical laboratories. The BMBL is not intended to be a regulatory document, although we recognize that some may use it in that way. We wish to emphasize that the sixth edition of BMBL remains an advisory document recommending best practices for the safe conduct of work in biomedical and clinical laboratories from a biosafety perspective. Biosafety in Microbiological and Biomedical Laboratories (BMBL) has served as the cornerstone of biosafety practice in the United States since its initial release in 1984.
0 Comments
Leave a Reply. |